Abstract
Hemodiafiltration (HDF) is not associated with lower mortality risk compared to standard hemodialysis (HD). However, there are many critical clinical outcomes in dialysis patients in addition to mortality; the impact of HDF on these other outcomes is not clear. This retrospective study included all patients referred to DaVita Clinics in the Kingdom of Saudi Arabia. High-flux HD was the initial modality in all patients. Those who did not achieve adequacy targets or those with poorly controlled phosphorus were switched to postdilution HDF using 18 to 23 L exchange per treatment. Patients dialyzing with a central venous catheter, patients who dialyzed less than 90 days at DaVita, and those with interrupted HDF were excluded. Of the 1115 patients, 215 (19%) were on HDF and 900 on high-flux HD; the median follow-up was 6 months for all patients. The HDF group showed a significant reduction in serum phosphate (P
Author supplied keywords
Cite
CITATION STYLE
Abdelsalam, M., Demerdash, T. M., Assem, M., Awais, M., Shaheen, M., Sabri, A., … Alsuwaida, A. (2021). Improvement of clinical outcomes in dialysis: No convincing superiority in dialysis efficacy using hemodiafiltration vs high-flux hemodialysis. Therapeutic Apheresis and Dialysis, 25(4), 483–489. https://doi.org/10.1111/1744-9987.13492
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.